Jagsonpal Pharmaceuticals Share Price

Jagsonpal Pharmaceuticals Investment Rating

• Master Rating:

• Jagsonpal Pharmaceuticals has an operating revenue of Rs. 226.69 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 12% is healthy, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 17% and 53% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 14% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 93 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 107 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.